# CJC-1295 FAQ — questions readers actually arrive with

> Plain answers to the questions readers actually ask about CJC-1295: the DAC distinction, half-life, the Phase 2 termination, FDA and WADA status, the ipamorelin pairing rationale, and tesamorelin comparisons.

Short, cited answers to the things people are usually trying to find out when they search for CJC-1295.

---

An editorial digest of peer-reviewed research — not a clinic, not a vendor, not a prescription.